4.8 • 3.1K Ratings
🗓️ 23 July 2024
⏱️ 70 minutes
🧾️ Download transcript
Click on a timestamp to play from that location
0:00.0 | Hi, I'm Christina Applegate. |
0:03.0 | And I'm Jamie Lynn Sigler. |
0:04.7 | And this is messy. The following message is brought to you by Navardis. Since partnering with |
0:18.9 | the Vardis I have been thinking a lot about when I was first diagnosed with relapsing a mess. |
0:24.4 | To be honest, I was overwhelmed and in denial and I didn't want to accept it. |
0:29.8 | Eventually I had to be real with myself, reflect on what was important, |
0:34.5 | reframe how my diagnosis was impacting my life, |
0:37.1 | and focus on how I was feeling. |
0:39.5 | And I wish I'd started thinking about my needs sooner. |
0:42.0 | It helped me get to a place of acceptance |
0:44.2 | and find the right treatment choice for me. |
0:46.2 | And I really hope others don't wait as long as I did. |
0:49.4 | That's why I partnered with Navardis |
0:51.5 | to create a three-step guide hoping it can help people speak up and voice |
0:56.1 | their needs. Get the guide at reframingMS.com. |
1:04.7 | Messy is supported by Sionic. The Sionic Neural Sleeve is the first FDA cleared bionic clothing designed to help people |
1:10.3 | living with MS and other neurological conditions |
1:12.8 | improve walking and strength. |
1:15.1 | For people living with MS, staying mobile and active is an essential part of |
1:18.4 | managing MS symptoms. |
1:20.1 | So the neurosleeve looks and feels like a garment instead of an assisted device and it's sleek |
1:24.4 | enough to fit under your clothing. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Wishbone Production, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Wishbone Production and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.